At a glance
- Originator Organon
- Class Antidepressants; Small molecules
- Mechanism of Action Alpha 2 adrenergic receptor antagonists; Biogenic monoamine uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Major depressive disorder
Most Recent Events
- 20 Feb 1997 New profile
- 20 Feb 1997 Discontinued-I for Depression in Netherlands (Unknown route)